The Form 4 filing, a report of an insider's stock activity, lists James C. Foster as a director. It was filed on October 26, 2026, for a transaction that took place on October 22, 2026.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-10-22 |
| Date of Latest Transaction | 2026-10-22 |
| Buy/Sell | sell |
| Transaction Count | 1 |
| Shares Transacted | 24,042 |
| Price | $350.00 |
| Total Transaction Value | $8,414,700.00 |
| Insider | |
| Ticker Symbol | CRL |
| Company | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. |
| Insider Name | FOSTER JAMES C |
| Insider Title | Director |
| Sector - Industry | Other - Unclassified |
| Holdings | |
| Total Shares Owned After Transaction | 31,596 |
| Position Size Change | 43.21% |
| Filing | |
| Filing Date | 2026-10-26 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a share sale, reported with transaction code S. It covers one sale of 24,042 CRL shares.
What was the average price of the transaction?
The average sale price was $350.00 per share.
How did this transaction affect the insider's holdings?
James C. Foster sold 24,042 shares and reported 31,596 shares owned afterward. The sale accounted for 43.21% of the shares he held before the sale.
What's the total transaction value?
The total reported value was $8,414,700.00 for the single sale.
Are there any special circumstances around this transaction?
The transaction information identifies a Rule 10b5-1 reference and a possible link to an exercise or conversion. Rule 10b5-1 plans set trading instructions in advance. The available details do not confirm whether a plan covered this sale or give its terms.
An exercise or conversion can mean using an existing right or exchanging another holding to receive shares. The possible link to this sale rests on a matching share count within the same filing. Only the sale entry is available here; the entry for shares received and the footnote text are missing. The share-count match alone does not confirm matching dates, share types, accounts, or that the same shares were sold.
For research purposes only; not investment advice.